Letermovir

Contraindicated

Letermovir Dihydroergotamine Injection DHE-45® Injection Increased ergot alkaloids exposure and an increased risk of ergotism Details Letermovir Dihydroergotamine Nasal Spray Migranal Increased ergot alkaloids exposure and an increased risk of ergotism Details

Major

Letermovir Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Letermovir Clindamycin ANTIROBE Explained Increased CYP3A substrate exposure Details Letermovir Omeprazole Gastrobim Explained Altered omeprazole exposure Details Letermovir Sertraline Explained Increased CYP3A substrate exposure Details Letermovir Buprenorphine Belbuca Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Letermovir Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Letermovir Simvastatin Flolipid Explained Increased simvastatin exposure and an increased risk for myopathy and rhabdomyolysis Details Letermovir Acalabrutinib Calquence Increased acalabrutinib exposure and increased risk of toxicity Details Letermovir Apixaban Eliquis Explained Increased CYP3A substrate exposure Details Letermovir Aripiprazole Injection Abilify Increased CYP3A substrate exposure Details Letermovir Atogepant Qulipta Increased atogepant exposure Details Letermovir Avapritinib Ayvakit Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Letermovir Avatrombopag Doptelet Increased CYP3A substrate exposure Details Letermovir Belumosudil Rezurock Explained Increased CYP3A substrate exposure Details Letermovir Atorvastatin Atorvaliq Increased atorvastatin exposure and an increased risk for myopathy and rhabdomyolysis Details Letermovir Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Letermovir Abiraterone Abirtega Increased CYP3A substrate exposure Details Letermovir Alfuzosin UroXatral Increased CYP3A substrate exposure Details Letermovir Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Letermovir Axitinib Inlyta Increased CYP3A substrate exposure Details Letermovir Bedaquiline Sirturo Increased bedaquiline exposure Details Letermovir Bosutinib Bosulif Increased bosutinib exposure Details Letermovir Brexpiprazole Rexulti Increased brexpiprazole exposure Details Letermovir Brigatinib Alunbrig Increased brigatinib exposure Details Letermovir Budesonide Entocort Increased budesonide exposure Details Letermovir Budesonide Nasal Spray Rhinocort Increased budesonide exposure Details Letermovir Budesonide Oral Inhalation Pulmicort Increased budesonide exposure Details Letermovir Cabozantinib Cabometyx Increased CYP3A substrate exposure Details Letermovir Cabozantinib (Thyroid Cancer) Cabometyx Increased CYP3A substrate exposure Details Letermovir Capmatinib Tabrecta Increased CYP3A substrate exposure Details Letermovir Clindamycin Injection ANTIROBE Increased CYP3A substrate exposure Details Letermovir Clindamycin Topical C/T/S® Increased CYP3A substrate exposure Details Letermovir Clindamycin Vaginal Cleocin Increased CYP3A substrate exposure Details Letermovir Cobimetinib Cotellic Increased cobimetinib plasma concentrations Details Letermovir Cyclosporine Injection Atopica Increased cycloSPORINE exposure and an increased letermovir exposure Details Letermovir Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure and an increased letermovir exposure Details Letermovir Darolutamide Nubeqa Increased exposure of OATP1B1 or OATP1B3 substrates Details Letermovir Dasatinib Phyrago Increased CYP3A substrate exposure Details